TITLE

SPECIALISED THERAPEUTICS/HELSINN GET PBS LISTING FOR ALOXI

PUB. DATE
December 2010
SOURCE
Worldwide Biotech;Dec2010, Vol. 22 Issue 12, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Specialised Therapeutics Australia Pty. Ltd. has been given exclusive license to distribute the anti-nausea and anti-vomiting drug for cancer patients called Aloxi in Australia and New Zealand. The distribution rights were granted under an agreement with Swiss Pharmaceutical Co. and the drug will be made available to the two countries under the Pharmaceutical Benefits Scheme. Aloxir has been described as a second generation 5-HT3 receptor antagonist.
ACCESSION #
55574813

 

Related Articles

  • Abraxis BioScience wins Australian approval for breast cancer drug.  // PharmaWatch: Cancer;Dec2008, Vol. 7 Issue 12, p11 

    The article reports on the approval received by the Abraxis BioScience Inc. and Specialised Therapeutics Australia Pty. Ltd. to market breast cancer drug in Australia. Abraxis and Specialized Therapeutics got the approval from the Therapeutic Goods Administration to market Abraxane 100 milligram...

  • Palonosetron hydrochloride.  // Australian Prescriber;Aug2011, Vol. 34 Issue 4, p121 

    The article offers information on Aloxi, a palonosetron hydrochloride treatment from Specialised Therapeutics Australia Pty. Ltd. The said medication is effective in treating vomiting, and nausea due to cytotoxic chemotherapy and cites its availability in five-milliliter vials. Palonosetron...

  • STA SIGNS LICENSE AGREEMENT WITH PHARMAMAR.  // Biotech Business;Sep2015, Vol. 28 Issue 9, p6 

    The article discusses a licensing and commercialization agreement signed by biopharmaceutical company Specialised Therapeutics Australia with European company PharmaMar under chairman José María Fdez for the marketing and distribution of oncology drug Aplidin plitidepsin in Australia and...

  • STA SIGNS LICENSE AGREEMENT WITH PHARMAMAR.  // Audiotex Update;Sep2015, Vol. 27 Issue 9, Special section p6 

    The article reports on the license agreement signed by biopharmaceutical company Specialised Therapeutics Australia (STA) with pharmaceutical company PharmaMar. It states that the agreement will enable STA to market and distribute the Aplidin anticancer drug in New Zealand and Australia. It adds...

  • Abraxis BioScience wins Australian approval for breast cancer drug.  // PharmaWatch: Biotechnology;Dec2008, Vol. 7 Issue 12, p11 

    The article reports that Abraxis BioScience Inc. and Specialised Therapeutics Australia Pty. Ltd. have received approval from the Therapeutic Goods Administration to market Abraxane 100mg powder for injection for the treatment of metastatic carcinoma of the breast after failure of anthracycline...

  • OTHER NEWS TO NOTE.  // BioWorld Today;10/17/2008, Vol. 19 Issue 203, p2 

    This section offers news briefs on biotechnology. An approval has been received by Abraxis BioScience Inc. and Specialised Therapeutics Australia Pty. Ltd. for Abraxene, its second-line treatment of metastatic breast cancer. A joint research agreement has been signed between Celsion Corp. and...

  • ARIAD SIGNS COMMERCIAL AGREEMENT FOR ICLUSIG.  // Worldwide Biotech;Apr2014, Vol. 26 Issue 4, p1 

    The article reports on the exclusive rights granted by ARIAD Pharmaceuticals Inc. to Specialised Therapeutics Australia Pty. Ltd. (STA) to sell its Philadelphia-positive (Ph+) leukemia drug Iclusig (ponatinib) in Australia. It states that STA will also be responsible for obtaining marketing...

  • NEWS HEADLINES: Other Cancers.  // PharmaWatch: Cancer;February 2003, Vol. 2 Issue 2, p20 

    Reports on global developments of drugs for cancer treatment as of January 2003. Endorsement of the investigational radioimmunotherapy Bexxar by the U.S. Food and Drug Administration; Launch of the first Ilex-sponsored study of Campath in non-Hodgkin's lymphoma by Ilex Oncology Inc.; Licensing...

  • ImmunoGen Signs $220M TAP Deal with Eli Lilly. Shaffer, Catherine // BioWorld Today;12/21/2011, Vol. 22 Issue 245, p1 

    The article reports on the license agreement signed by ImmunoGen Inc. with Eli Lilly and Co. for the use of its maytansinoid targeted antibody payload (TAP) technology in the development of antibody-drug conjugates for cancer. ImmunoGen will receive 20 million U.S. dollars and 200 million U.S....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics